PMID- 23237661
OWN - NLM
STAT- MEDLINE
DCOM- 20131204
LR  - 20130430
IS  - 1873-4022 (Electronic)
IS  - 1873-4022 (Linking)
VI  - 38
IP  - 2
DP  - 2013 Summer
TI  - Implementing intensity modulated radiotherapy to the prostate bed: dosimetric 
      study and early clinical results.
PG  - 117-21
LID - S0958-3947(12)00167-7 [pii]
LID - 10.1016/j.meddos.2012.09.001 [doi]
AB  - Salvage intensity modulated radiotherapy (IMRT) to the prostate bed has hardly 
      been studied so far. We present here a feasibility study and early clinical 
      results for 10 patients. These patients were selected on the basis of having 
      either a biochemical relapse or high risk histology after prostatectomy. They 
      were treated using "sliding-window" IMRT to 68 Gy in 34 fractions. 
      Three-dimensional conformal radiotherapy (3D-CRT) plans were generated using the 
      same planning computed tomography data set. Dose coverage of planning target 
      volumes (PTVs) and of organs-at-risk (OAR, namely: rectum, bladder, and femoral 
      heads) were compared. Acute toxicity and chronic toxicity were measured using the 
      Common Toxicity Criteria for Adverse Events version 3.0 scale. IMRT significantly 
      reduces the dose above the prescription dose given to the PTV1 (mean dose: IMRT 
      67.2 Gy vs 3D-CRT 67.7 Gy (p = 0.0137)), without altering dose coverage for PTV2 
      (mean dose: IMRT 68.1 Gy vs 3D-CRT 68.0 Gy (p = 0.3750)). Doses to OAR were lower 
      with IMRT and differences were statistically significant (mean dose: IMRT 51.4 Gy 
      vs 3D-CRT 56.6 Gy for rectum (p = 0.002), IMRT 45.1 Gy vs 3D-CRT 53.1 Gy for 
      bladder (p = 0.002), and IMRT 26.1 Gy vs 3D-CRT 28.4 Gy for femoral heads (p = 
      0.0059)). There was no acute or chronic genitourinary or gastrointestinal 
      toxicity >1 with a median follow-up of 38 months. IMRT to the prostatic fossa is 
      feasible and reduces dose to OAR, with consequential limited toxicity.
CI  - Copyright (c) 2013 American Association of Medical Dosimetrists. Published by 
      Elsevier Inc. All rights reserved.
FAU - Riou, Olivier
AU  - Riou O
AD  - Departement de Cancerologie Radiotherapie, CRLC Val d'Aurelle-Paul Lamarque, 
      Montpellier, France. riouo@hotmail.com
FAU - Laliberte, Benoit
AU  - Laliberte B
FAU - Azria, David
AU  - Azria D
FAU - Menkarios, Cathy
AU  - Menkarios C
FAU - Llacer Moscardo, Carmen
AU  - Llacer Moscardo C
FAU - Dubois, Jean-Bernard
AU  - Dubois JB
FAU - Ailleres, Norbert
AU  - Ailleres N
FAU - Fenoglietto, Pascal
AU  - Fenoglietto P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20121211
PL  - United States
TA  - Med Dosim
JT  - Medical dosimetry : official journal of the American Association of Medical 
      Dosimetrists
JID - 8908862
SB  - IM
MH  - Aged
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prostatic Neoplasms/*radiotherapy
MH  - Radiometry/*methods
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Radiotherapy, Adjuvant/methods
MH  - Radiotherapy, Conformal/*methods
MH  - Salvage Therapy/*methods
MH  - Treatment Outcome
EDAT- 2012/12/15 06:00
MHDA- 2013/12/16 06:00
CRDT- 2012/12/15 06:00
PHST- 2012/01/06 00:00 [received]
PHST- 2012/07/23 00:00 [revised]
PHST- 2012/09/13 00:00 [accepted]
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0958-3947(12)00167-7 [pii]
AID - 10.1016/j.meddos.2012.09.001 [doi]
PST - ppublish
SO  - Med Dosim. 2013 Summer;38(2):117-21. doi: 10.1016/j.meddos.2012.09.001. Epub 2012 
      Dec 11.